Susan G. Barr, BSc, MSc, MD, FRCPC

Associate Professor, Division of Rheumatology, Departments of Medicine and Community Health Sciences Director, Rheumatology Residency Training Program

RESEARCH INTERESTS AND ACTIVITIES

Key Words: systemic lupus erythematosus, rheumatoid arthritis, biologic agents, epidemiology

As Co-director of the Pharmacovigilance Program, Dr. Barr is involved in research on the effectiveness and safety of biologic agents for rheumatoid arthritis in usual clinical practice. In collaboration with colleagues in Edmonton, this work has expanded to a Province-wide program under the Alberta Biologics for Inflammatory Arthritis Research Initiative. She is also involved in collaborative research with the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS) ongoing multicentre studies, including malignancy in lupus and the genetic and environmental risk factors for lupus. In addition, Dr. Barr is interested in access to health services and has directed the successful implementation of the Central Referral and Triage in Rheumatology (CReATe Rheum) Program, with the goal of having the right patient see the right physician at the right time. This is of critical importance for patients with early inflammatory arthritis and this program has aided in the development of our Early Arthritis Clinic and other Specialty Clinics.

RESEARCH IN PROGRESS

ROLE	FUNDING AGENCY	TITLE OF PROJECT	ALLOCATION
Co- Investigator	Veterans Administration and the Canadian Arthritis Network	Rheumatoid arthritis: Comparison of active therapies in patients with active disease despite methotrexate therapy (RACAT)	ongoing
	Alberta Health	Biologics pharmacovigilance program: Monitoring the safety and effectiveness of biologic agents for the treatment of systemic rheumatic diseases	ongoing

2010/11

PUBLICATIONS

Peer-Reviewed Journal Article

Budarf ML, Goyette P, Boucher G, Lian J, Graham RR, Claudio JO, Hudson T, **Barr SG**, Boire G, Clarke AE, Gladman D, Hanly J, Peschken C, Pope JE, Rich E, Smith CD, Summer M, Fortin PR, Wither J, Rioux JD. A targeted association study in systemic lupus erythematosus (SLE) identifies novel risk alleles and replicates known susceptibility alleles. *Genes and Immunity* 2011;12(1):51-8.

Abstracts Published in Journals

Barnabe C, Martin L, Boyd S, **Barr SG**. Application of high resolution peripheral quantitative computed tomography (HR-pQCT) to quantify bony damage in rheumatoid arthritis. *Arthritis and Rheumatism* 2010;62(10):S49.

- Ohinmaa A, Martin L, Russell AS, Barr SG, Sholter D, Penney C, Yan C, Jacobs P, Maksymowych WP. Primary anti-TNF failures experience superior clinical responses to a second anti-TNF agent than secondary failures: Analysis of switching data in the Alberta Rheumatoid Arthritis Biologics Registry. *Value in Health* 2010;13(7):A303.
- Barnabe C, Joseph L, Edworthy S, Belisle P, Svenson L, Labrecque J, Hemmelgarn B, **Barr SG**, Bernatsky S. The prevalence of systemic lupus in Alberta: A population-based assessment. *Journal of Rheumatology* 2011;38(6):1173.
- Barnabe C, Martin L, Boyd S, **Barr SG**. Application of high-resolution peripheral quantitative computed tomography to diagnose and quantify bony damage in rheumtoid arthritis. *Journal of Rheumatology* 2011;38(6):1133.
- Barnabe C, Joseph L, Edworthy S, Belisle P, Svenson L, Labrecque J, Hemmelgarn B, **Barr SG**, Bernatsky S. Scleroderma prevalence in Alberta: A population-based assessment. *Journal of Rheumatology* 2011;38(6):1151.

GRADUATE STUDENT SUPERVISION

Cheryl Barnabe, MSc student, Department of Community Health Sciences
Thesis Topic: Assessment of bony damage using high resolution peripheral quantitative computed tomography (HR-pQCT) in rheumatoid arthritis